Trial Condition(s):
Premenstrual Syndrome, Contraceptives, Oral
Study to assess efficacy of a monophasic oral contraceptive preparation containing Drospirenone 3 mg/Ethinylestradiol 20 μg in the treatment of Premenstrual Dysphonic Disorder
Bayer Identifier:
91001
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
65
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
YAZ (EE20/DRSP, BAY86-5300)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation, Containing Drospirenone 3 mg/Ethinyl Estradiol 20 μg (as Beta-Cyclodextrin Clathrate), in the treatment of Premenstrual Dysphoric Disorder (PMDD)
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
